2024年8月24日:OKYO药业和SolarMax技术将在博电视台的RedChip小股票,大钱TM节目中接受采访. 24 Aug 2024: OKYO Pharma and SolarMax Technology to be interviewed on Bloomberg TV's RedChip Small Stocks, Big Money™ show.
2024年8月24日,临床阶段生物制药公司OKYO Pharma Ltd. (纳斯达克:OKYO) 和太阳能公司SolarMax Technology, Inc. (纳斯达克:SMXT) 将在博电视台的RedChip小股票,大钱TM节目中接受采访. On August 24, 2024, clinical-stage biopharmaceutical company OKYO Pharma Ltd. (Nasdaq: OKYO) and solar energy company SolarMax Technology, Inc. (Nasdaq: SMXT) will be featured in interviews on Bloomberg TV's RedChip Small Stocks, Big Money™ show. OKYO Pharma正在采用一种独特的脂质混杂化学激素浸泡剂方法,为干眼病(DED)和神经病症角痛症(NCP)开发创新疗法,主要候选人OK-101显示最近对DED的第二阶段试验取得了显著进展,并具有治疗NCP的巨大潜力。 OKYO Pharma is developing innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP) using a unique lipid-conjugated chemerin peptide approach, with lead candidate OK-101 demonstrating notable improvements in a recent Phase 2 trial for DED and significant potential for treating NCP. 索拉麦技术公司已完成了15 000多个装置,并正在战略性地扩大美国商业太阳能开发服务的规模,在拉斯维加斯和圣何塞实施了大型项目。 SolarMax Technology has completed over 15,000 installations and is strategically scaling commercial solar development services in the US, with large-scale projects in Las Vegas and San Jose.